Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076378" target="_blank" >RIV/65269705:_____/22:00076378 - isvavai.cz</a>
Výsledek na webu
<a href="https://ashpublications.org/blood/article-abstract/140/3/285/485155/Prospective-comparison-of-outcomes-with?redirectedFrom=fulltext" target="_blank" >https://ashpublications.org/blood/article-abstract/140/3/285/485155/Prospective-comparison-of-outcomes-with?redirectedFrom=fulltext</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2022015832" target="_blank" >10.1182/blood.2022015832</a>

Jazyk výsledku
angličtina
Název v původním jazyce
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Popis výsledku v původním jazyce
The hypomethylating agents azacitidine (AZA) and decitabine (DEC) have been backbone therapies for older or unfit patients with newly diagnosed acute myeloid leukemia (AML) as single agents and, more recently, in combination with venetoclax.1-5 Despite being widely used for .15 years, AZA and DEC have not been directly compared in a large randomized trial. Here, we sought to indirectly compare the clinical outcomes with DEC or AZA in this patient population in the context of a large prospective trial. All patients provided signed informed consent.
Název v anglickém jazyce
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Popis výsledku anglicky
The hypomethylating agents azacitidine (AZA) and decitabine (DEC) have been backbone therapies for older or unfit patients with newly diagnosed acute myeloid leukemia (AML) as single agents and, more recently, in combination with venetoclax.1-5 Despite being widely used for .15 years, AZA and DEC have not been directly compared in a large randomized trial. Here, we sought to indirectly compare the clinical outcomes with DEC or AZA in this patient population in the context of a large prospective trial. All patients provided signed informed consent.

Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)